Immunic to Participate in Investor, Industry and Scientific Conferences in June
As SpaceX reportedly snips IPO valuation, prediction markets are still saying it will be a $2 trillion company
Immunic presents new vidofludimus calcium data at multiple sclerosis conference
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
Immunic presents new vidofludimus calcium data at multiple sclerosis conference
FTSE 100 Live: Global markets hit record highs, oil prices slide as Iran deal awaited
Amazon shares have room to run as AWS AI backlog hits $35B, UBS says
Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials
Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer
Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials
EXCLUSIVE: Immunic Appoints Former Genentech Exec Erik Lundgren As CEO
Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout
Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
Immunic advances Phase 3 MS program, eyes topline data by year-end
Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
Immunic advances Phase 3 MS program, eyes topline data by year-end
Immunic: Saved By A 200 Million Private Placement
Immunic to Participate in Investor and Medical Conferences in May
Immunic appoints Michael Panzara as CMO ahead of pivotal MS drug readout
Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D.
Immunic to implement 1-for-10 reverse stock split
Immunic, Inc. Announces 1-for-10 Reverse Stock Split
ServiceNow shares fall as growth and margin concerns weigh on outlook
Immunic's Next-Gen Oral Multiple Sclerosis Drug Poised To Capture Share, Analyst Says
Immunic to Participate in Scientific and Medical Conferences in April
Immunic to present lead MS therapy at April conferences
Nasdaq leads markets lower as Iran says 'restraint is ended' ahead of Trump deadline
Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement
Immunic appoints biopharmaceutical executive Jon Congleton to board
Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton
Immunic appoints biopharmaceutical executive Jon Congleton to board
Stock Market Today, March 24: Oil, AI, and Private Credit Fears Weigh on Markets
Immunic secures European patent for MS drug candidate vidofludimus calcium
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
Critical Analysis: Immunic (NASDAQ:IMUX) and Neuphoria Therapeutics (NASDAQ:NEUP)
Immunic to present at healthcare investor conferences in March
UBS raises memory chip price targets as supply crunch deepens, defying sector sell-off
Immunic to Participate in Investor Conferences in March
FTSE 100 Live: London sell-off may be 'muted' as markets react to Iran war
Immunic secures $400M to support late-stage MS trials - ICYMI
Immunic secures $400M to support late-stage MS trials - ICYMI
Immunic sets stage for phase 3 MS data readout after $400M financing
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
Immunic, Inc. (NASDAQ:IMUX) Receives Average Rating of “Buy” from Analysts
FTSE 100 Live: Index powers to new highs as CPI falls, miners and defence in demand
Immunic closes $200M private placement to fund late-stage MS trials
Immunic Announces Closing of Oversubscribed Private Placement Financing
Immunic closes $200M private placement to fund late-stage MS trials
Immunic MS trial shows reduced brain lesions - ICYMI
Immunic MS trial shows reduced brain lesions - ICYMI